A tetravalent bispecific protein enables targeted degradation of VCAM-1 and VEGFR for treatment of choroidal neovascularization
Proceedings of the National Academy of Sciences, Volume 123, Issue 45, November 2026. SignificanceCurrent anti-vascular endothelial growth factor therapies for wet age-related macular degeneration (AMD) lack selectivity for pathological vessels, leading to suboptimal efficacy and off-target effects.